Thanks Eire.
I confess I hadn't factored-in 006 at all. I definitely was of the mind that 008 was just too small to confirm DMOAD for labelling purposes, and existed only to enhance the case for DM ahead of partnership discussions (plus help meet TGA criteria to start selling in Aus).
006 clearly has much more scope to take that enhanced understanding of Zilosuls DM properties, and apply greater scientific rigour to confirm DMOAD status for labelling purposes.
Maybe if the 008 results are compelling, there is a discussion to be had about raising capital to take this the whole way through 002 and 006 before partnering for sales and distribution? Surely there would be a bonafide bidding frenzy amongst the pharma giants if PAR found themselves in patent-covered, supply-cornered possession of history's first fully-approved DMOAD for human use?
- Forums
- ASX - By Stock
- PAR
- Ann: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION
Ann: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION, page-189
-
- There are more pages in this discussion • 106 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M |
Open | High | Low | Value | Volume |
20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 387930 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 65468 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 384246 | 0.190 |
3 | 57000 | 0.185 |
8 | 194873 | 0.180 |
6 | 140904 | 0.175 |
7 | 595605 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 65468 | 2 |
0.210 | 25992 | 3 |
0.215 | 30000 | 1 |
0.220 | 27066 | 4 |
0.225 | 21604 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |